Drugplain

Theo-24 200 mg/1

theophylline anhydrous · CAPSULE, EXTENDED RELEASE · ENDO USA, Inc.

No Recall History
Plain English

Theo-24 is a prescription medication containing theophylline, a methylxanthine drug used to treat and prevent symptoms of asthma and chronic obstructive pulmonary disease (COPD). It comes as an extended-release capsule taken by mouth, allowing the medication to work over an extended period.

Key Facts

Brand Name
Theo-24
Generic Name
theophylline anhydrous
NDC Code (Product)
52244-200
Manufacturer
ENDO USA, Inc.
Strength
200 mg/1
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Marketing Status
Application #
ANDA087943
Drug Class
Methylxanthine [EPC]
Marketing Start
08/25/2014

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

dyspnoea150 reports
asthma116 reports
pneumonia86 reports
wheezing62 reports
toxicity to various agents58 reports
vomiting58 reports
cough56 reports
nausea49 reports
drug ineffective48 reports
fatigue48 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

INDICATIONS AND USAGE Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.

Dosage & Administration

DOSAGE AND ADMINISTRATION General Considerations: Theo-24, like other extended-release theophylline products, is intended for patients with relatively continuous or recurring symptoms who have a need to maintain therapeutic serum levels of theophylline. It is not intended for patients experiencing an acute episode of bronchospasm (associated with asthma, chronic bronchitis, or emphysema). Such patients require rapid relief of symptoms and should be treated with an immediate-release or intravenous theophylline preparation (or other bronchodilators) and not with extended-release products. Patients who metabolize theophylline at a normal or slow rate are reasonable candidates for once-daily dosing with Theo-24. Patients who metabolize theophylline rapidly (e.g., the young, smokers, and some nonsmoking adults) and who have symptoms repeatedly at the end of a dosing interval, will require either increased doses given once a day or preferably, are likely to be better controlled by a schedule of twice-daily dosing. Those patients who require increased daily doses are more likely to experience relatively wide peak-trough differences and may be candidates for twice-a-day dosing with Theo-24

Warnings

WARNINGS Concurrent Illness: Theophylline should be used with extreme caution in patients with the following clinical conditions due to the increased risk of exacerbation of the concurrent condition: Active peptic ulcer disease Seizure disorders Cardiac arrhythmias (not including bradyarrhythmias) Conditions That Reduce Theophylline Clearance There are several readily identifiable causes of reduced theophylline clearance. If the total daily dose is not appropriately reduced in the presence of these risk factors, severe and potentially fatal theophylline toxicity can occur. Careful consideration must be given to the benefits and risks of theophylline use and the need for more intensive monitoring of serum theophylline concentrations in patients with the following risk factors: Age Neonates (term and premature) Children <1 year Elderly (>60 years) Concurrent Diseases Acute pulmonary edema Congestive heart failure Cor-pulmonale Fever; ≥102°F for 24 hours or more; or lesser temperature elevations for longer periods Hypothyroidism Liver disease; cirrhosis, acute hepatitis Reduced renal function in infants <3 months of age Sepsis with multi-organ failure Shock Cessation of Smoking Drug I

Contraindications

CONTRAINDICATIONS Theo-24 is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product.

Drug Interactions

Drug Interactions: Drug/Drug Interactions Theophylline interacts with a wide variety of drugs. The interaction may be pharmacodynamic, i.e., alterations in the therapeutic response to theophylline or another drug or occurrence of adverse effects without a change in serum theophylline concentration. More frequently, however, the interaction is pharmacokinetic, i.e., the rate of theophylline clearance is altered by another drug resulting in increased or decreased serum theophylline concentrations. Theophylline only rarely alters the pharmacokinetics of other drugs. The drugs listed in Table II have the potential to produce clinically significant pharmacodynamic or pharmacokinetic interactions with theophylline. The information in the "Effect " column of Table II assumes that the interacting drug is being added to a steady-state theophylline regimen. If theophylline is being initiated in a patient who is already taking a drug that inhibits theophylline clearance (e.g., cimetidine, erythromycin), the dose of theophylline required to achieve a therapeutic serum theophylline concentration will be smaller. Conversely, if theophylline is being initiated in a patient who is already taking a

Adverse Reactions

ADVERSE REACTIONS Adverse reactions associated with theophylline are generally mild when peak serum theophylline concentrations are <20 mcg/mL and mainly consist of transient caffeine-like adverse effects such as nausea, vomiting, headache, and insomnia. When peak serum theophylline concentrations exceed 20 mcg/mL, however, theophylline produces a wide range of adverse reactions including persistent vomiting, cardiac arrhythmias, and intractable seizures which can be lethal (see OVERDOSAGE ). The transient caffeine-like adverse reactions occur in about 50% of patients when theophylline therapy is initiated at doses higher than recommended initial doses (e.g., >300 mg/day in adults and >12 mg/kg/day in children beyond 1 year of age). During the initiation of theophylline therapy, caffeine-like adverse effects may transiently alter patient behavior, especially in school age children, but this response rarely persists. Initiation of theophylline therapy at a low dose with subsequent slow titration to a predetermined age-related maximum dose will significantly reduce the frequency of these transient adverse effects (see DOSAGE AND ADMINISTRATION , Table V). In a small percentage of pat

Frequently Asked Questions

What is Theo-24 used for?

Theo-24 is a prescription medication containing theophylline, a methylxanthine drug used to treat and prevent symptoms of asthma and chronic obstructive pulmonary disease (COPD). It comes as an extended-release capsule taken by mouth, allowing the medication to work over an extended period.

Is Theo-24 a controlled substance?

Theo-24 is not classified as a controlled substance by the DEA.

What is the generic name for Theo-24?

The generic name for Theo-24 is theophylline anhydrous. There are 2 other brand versions of theophylline anhydrous.

What is the NDC code for Theo-24 200 mg/1?

The NDC (National Drug Code) for Theo-24 200 mg/1 is 52244-200, listed by ENDO USA, Inc..

Product NDC

52244-200

Package NDC

52244-200-10

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)